**TÍTULO:**

Artrite reumatóide em coorte de doentes submetidos a terapêutica biológica: monitorização padronizada num centro terciário de referenciação em Portugal.

**TITLE:**

Biotechnological therapy in a cohort of patients with rheumatoid arthritis: results based on standardized monitoring in a tertiary center in Portugal

**AUTORES:**

Melissa Fernandes (Internato de Medicina Interna), Estágio na Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.

Adelaide Figueiredo (Internato de Medicina Interna), Estágio na Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal; Serviço de Medicina IV, Hospital de Santarém EPE, Santarém, Portugal.

Ana Luisa Oliveira (Internato de Medicina Interna), Estágio na Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal; Serviço de Medicina I, Hospital José Joaquim Fernandes, Unidade Local de Saúde do Baixo Alentejo, Beja, Portugal.

Ana Carolina Ferreira (Internato de Medicina Interna), Estágio na Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal; Serviço de Medicina Interna, Hospital do Divino Espírito Santo de Ponta Delgada EPE, Ponta Delgada, Portugal.

Pedro Mendonça (Internato de Medicina Interna), Estágio na Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal; Serviço de Medicina, Hospital de Faro, Centro Hospitalar Universitário do Algarve, Faro, Portugal.

Anna V Taulaigo (Internato de Medicina Interna), Estágio na Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.

Madalena Vicente (Internato de Medicina Interna), Estágio na Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.

Maria João Fanica (Farmacêutica Assistente), Serviços Farmacêuticos, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.

Carina Ruano (Assistente Hospitalar), Serviço de Radiologia, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.

António Panarra (Chefe de Serviço), Director do Serviço de Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.

Céu Mateus (Professor of Health Economics), Division of Health Research Lancaster University, Furness College, Reino Unido.

Maria Francisca Moraes-Fontes (Assistente Hospitalar Graduada), Coordenadora da Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.

**Corresponding Author:**

Maria Francisca Moraes-Fontes

Address: Unidade de Doenças Auto-imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário Lisboa Central, Rua da Beneficância, 8, 1069-166 Lisboa, Portugal

e-mail: mffontes61@gmail.com

**BRIEF TITLE FOR A HEADING:** Biotechnological therapy in rheumatoid arthritis: results based on standardized monitoring in an outpatient clinic in Portugal

**TÍTULO:**

Artrite reumatóide em coorte de doentes submetidos a terapêutica biológica: monitorização padronizada num centro terciário de referenciação em Portugal.

**TITLE:**

Biotechnological therapy in a cohort of patients with rheumatoid arthritis: results based on standardized monitoring in a tertiary center in Portugal

**ABSTRACT EM PORTUGUÊS**

INTRODUÇÃO:

Avanços no tratamento da artrite reumatóide contribuiram para uma evolução favorável. Apesar de evidências substanciais provenientes de ensaios clínicos, são menos conhecidos dados de vida real. O objetivo do estudo foi caracterizar a doença e a qualidade de vida em doentes sob fármacos biotecnológicos.

MÉTODOS:

Estudo transversal de coorte sendo recolhidos dados clínicos, relativos à adesão terapêutica, atividade da doença, capacidade funcional, deformidades articulares, comorbilidades e questionários de Qualidade de Vida relacionada com a saúde, estado civil, situação profissional e escolaridade.

RESULTADOS:

Foram recrutados 77 do grupo original de um total de 94 doentes. A mediana da idade foi 63 anos, 82% do sexo feminino e início de biológico cerca de 4 anos após o início da doença, com uma mediana de duração de 12 anos. De acordo com o *Disease Activity Score* (DAS28), a % de doentes com atividade alta, moderada, baixa ou em remissão mudou, respectivamente, de 50, 45, 0 e 5 pré- biológico para 11, 37, 25 e 26 na altura da re-avaliação, com melhoria funcional. Setenta e cinco % dos doentes mantiveram o tratamento original com boa adesão. Pontuações mais baixas do *Short Form-36* associaram-se a uma baixa pontuação no *EQ-5D-3L*. Uma menor esperança de vida aos 10 anos assim como uma maior discontinuação da terapêutica biológica foram observadas no grupo de doentes que vieram a falecer (n=6).

CONCLUSÕES:

Não obstante ajustes terapêuticos e seguimento regular, uma % significativa de doentes mantinha atividade moderada e limitação funcional com baixa qualidade de vida relacionada com a saúde.

**ABSTRACT**

INTRODUCTION:

Clinical outcomes in rheumatoid arthritis have greatly improved with therapeutic advances. Despite intense trial observations, there is a lack of real life data. The aim of this study was to assess disease status and quality of life in an outpatient population treated with biotechnological disease-modifying anti-rheumatic drugs.

METHODS:

Cross-sectional cohort study recalling all patients ever treated in our unit with biotechnological disease-modifying anti-rheumatic drugs. Clinical and demographic data, compliance, disease activity, functional status, joint deformities, and comorbidities were documented, and patients queried on occupational status, education, marital status and generic Health Related Quality of Life questionnaires.

RESULTS:

Recall was attended by 77 of the original 94 patients. At recall, median age was 63, 82% female and the median disease duration was 12 years. Biological therapy was started a median 4 years following disease onset. According to the Disease Activity Score (DAS28), the % of patients with high, moderate, low disease activity or remission changed from 50, 45, 0 and 5 (pre-therapy) to 11, 37, 25 and 26 at recall, respectively; functional status was significantly improved. Seventy-five % of patients retained the original treatment with good compliance. Lower Short Form-36 domain scores accompanied a low EQ-5D-3L score. Deceased patients (n=6) had a lower estimated 10-year survival rate. In this group, biological therapy was discontinued at a higher frequency during follow-up.

CONCLUSIONS:

In spite of therapy switches and regular follow-up, a significant % of patients still presented with moderate disease activity, functional impairment and a poor Health-related Quality of Life.

**KEYWORDS:** Rheumatoid Arthritis, Health-related Quality of Life, Biotechnological Therapy

**INTRODUCTION**

Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease predominantly characterized by chronic inflammation of synovial joints. Without appropriate therapy the disease almost inevitably leads to severe joint deformities, particularly of the hands, chronic pain and suffering, disability, inability to work, poor quality of life and early mortality.**1** Chronic glucocorticoids and non-steroidal anti-inflammatory drugs used from the 1950´s failed to control disease and had too many associated side-effects, often life-threatening.**2** The era of innovative medicine occurred in the late 1990’s with the focus shifted to a treat to target–based approach, with new treatment paradigms, including early diagnosis and an intensive management approach. This was made possible through the use of biotechnological disease-modifying anti-rheumatic drugs (bDMARD) in addition or as an alternative to synthetic disease-modifying anti-rheumatic drugs (sDMARD).**3,4,5** The first biological therapies to be developed in rheumatology were the tumor necrosis factor inhibitors (TNFi) for patients who failed treatment with sDMARDs.**4,6** Most importantly, the therapeutic judgment has to take into account co-morbidities (such as heart failure and infectious risk), past history of neoplasia and ideally identify those with a high risk of relapse.**6** Currently there is a much wider therapeutic armamentarium ranging from membrane receptor agonists or antagonists (Fc-CTLA4, CD20), anti-cytokine (Il-6, IL-17) to JAK kinase inhibitors.**7**

Despite advances there are still no easily assessable bio-markers to establish a personalized treatment approach at the time of disease onset or diagnosis. Similarly, during follow-up most therapeutic decisions frequently remain empirical. This is the case when tentatively adapting the chosen therapy to a personalized optimal dose and regimen, but also when prescribing co-therapies or switching to other bDMARD when the treatment is inefficient, or associated with intolerance or adverse events. Furthermore, therapies may be ineffective (wrong target) or become neutralized due to their immunogenicity. Of note, in Portugal, these therapies are entirely state subsidized and are associated with a significant societal cost.

Clinical assessment of disease activity, progression and remission are robust and quantitative,8 as are indicators of a patient’s quality of life. In this work we aimed to study every single patient with RA that ever received biological therapy in our Unit and answer some very simple questions that nevertheless remain at the core of the major investment for these patients. Are our patients free of deformities? Are they able to work and do they lead productive lives? Have they retained their original therapies? Was a switch required? Was therapy interrupted and for what reason? Have they suffered important side-effects? Do they suffer from important co-morbidities? Have we lost patients to follow-up? Are they alive?

**MATERIALS AND METHODS**

**1. STUDY DESIGN AND POPULATION**

This is a cross-sectional study that took place in an outpatient care setting between December 2017 and May 2018. We only included patients that were on biological therapy for at least three months. All fulfilled the American College of Rheumatology 1987**9** and 2010**10** revised criteria for the classification of Rheumatoid Arthritis (RA) and were aged ≥18 years. Our Unit´s database allowed us to identify 94 patients with RA that started biological therapy (bDMARD) from 01/2002 (date of first bDMARD treatment in the Unit) to 12/2017. At the time of recall, seven patients were lost to follow-up, six patients had died, and four refused to participate in our study. Overall, recall involved 77 patients. Each patient underwent a physical examination, recording of disease activity and hand joint deformities and was requested to complete a questionnaire regarding demographic and social characteristics as well as generic Health Related Quality of Life (HR-QoL) questionnaires validated for Portugal. Demographic and clinical data was also extracted from the medical records. The Charlson Comorbidity Index (CCI)**11** which predicts 10-year survival in patients with multiple comorbidities was calculated for all patients at onset of bDMARD therapy and at time of recall. Pharmacy refill information was obtained for every patient under self-administered biological therapy. The study was registered at EuroQol Group website (14th July 2013) and collaboration was obtained from Professor Pedro Lopes Ferreira (24th January 2015). The study protocol was approved by the hospital Ethics Committee (process 183/2015) and the *Comissão Nacional de Protecção de Dados* (3886/2016).

**2. THERAPEUTIC APPROACH**

In the latter years, a T2T approach was followed according to recommendations.**5** When a TNFi patient was intolerant to methotrexate, failed to reach at least low disease activity or presented with poor prognostic signs, a switch was performed, to rituximab, tocilizumab or abatacept, depending on prior medical history and comorbidities and also according to marketing authorizations and ministry of health re-imbursement policies at the time. Rituximab was administered at the dose of 1 g, 2 weeks apart, with the exception of one patient with Sjögren´s syndrome that received 375 mg/m2 – 4 doses, weekly. Prednisolone was tapered and discontinued whenever possible.

**3. DISEASE ACTIVITY AND DEFORMITIES**

Disease activity was measured by Disease Activity Score 28-erythrocyte sedimentation rate [DAS28-ESR]**12** defined as follows: high disease activity (HDA) > 5.1; moderate disease activity (MDA) ≥ 3.2 and ≤5.1; low disease activity (LDA) ≥ 2.6 and < 3.2; remission < 2.6. DAS28-ESR was routinely recorded at clinic visits. In a subset of patients, at recall, the physician counted the number of wrist and hand deformities per patient.

**4. HEALTH ASSESSMENT QUESTIONNAIRE**

The functional status was measured by the health assessment questionnaire (HAQ). The HAQ consists of eight categories which evaluate the patient’s difficulty with activities of daily living over the past week. The questionnaire consists of 41 total items: 20 specific activities are grouped into 8 functional categories with each category given a single score equal to the maximum value of their component activities, 13 additional questions on the use of assistive devices, and 8 additional questions assessing help received from others using a scale 0, 1, 2 or 3. The patient's responses were recorded on a scale from zero (no disability) to three (completely disabled).**13-16**

**5. PATIENT COMPLIANCE**

Compliance was determined by the proportion of days covered (PDC) for the index biologic during the 12-month follow-up period. Non-compliance of self-administered biologics (etanercept adalimumab, golimumab and tocilizumab) was defined as proportion of days covered <80% during the post index period.**17** Patient compliance was obtained by using pharmacy refill information for the duration of one year prior to recall visit. Patients were considered non-compliant with medication when less than 80% of prescriptions were collected from the pharmacy. Patients under intravenous medication (rituximab, tocilizumab, infliximab, and abatacept) were considered compliant since in our Unit qualified nurses perform administration of biologics in a Day Hospital.

**6. HEALTH RELATED QUALITY OF LIFE**

 HR-QoL, defined as those aspects of quality of life that directly or indirectly relate to health, a concept that includes physical, psychological, and social domains, was measured through the Short Form (SF-36) Health Survey and the EuroQoL Group 5D-3L (EQ-5D-3L).

 SF-36 is a 36-item, patient-reported survey consisting of eight scaled scores, which are the weighted sums of the questions in their section. Some questions have an inverted scale. After each scale is directly transformed into a 0-100 scale, the lower the score the higher the disability, in other words, a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight dimensions are: vitality (V), physical functioning (PF), bodily pain (BP), general health perceptions (GH), physical role functioning (RP), emotional role functioning (RE), social role functioning (SF) and mental health (MH). Scoring algorithms allow for aggregating scores from the eight SF-36 subscales in two distinct scores: a Physical Component Summary (PCS) and a Mental Component Summary (MCS). In the present study, SF-36 was analysed according to the norms for the Portuguese population.**18,19**

Each patient was asked to report their socio-demographic characteristics (age, gender, marital status) and complete the EQ-5D-3L in order to self-report their own health in a five-dimension descriptive system (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each attribute has three levels: no problems, some problems, and severe problems, resulting in 243 possible health states, the best of which corresponds to a score of 1. Each health state was then assigned an index value by applying scores from national Portuguese preference weights (tariffs) using a validated model,**20,21** Patients were asked to place a markon a Visual Analogue Scale (VAS) ranging from endpoints 0 for the ‘worst imaginable health state’ to 100 for the ‘best imaginable health state’.

**7. Statistical analysis**

According to the normality of their sampling distributions, continuous variables were recorded as means (± standard deviation) or medians (IQR1 - IQR3). Dichotomous variables were examined by frequency distribution, recorded as percentage, and comparisons were made using the Chi-square test or Fisher’s exact test for independent samples. The T test was used for comparison between normally distributed variables. For continuous data that were not normally distributed, the Wilcoxon Signed Rank test was used to compare paired means and the Mann-Whitney *U* test for comparisons between independent samples. Correlations between continuous variables were analysed with Pearson's correlation coefficient. A p value < than 0.05 was considered statistically significant. Analyses were performed using SPSS version 23 software.

**RESULTS**

**Result 1. Initial Patient Cohort: demographic and clinical features**

Overall 94 patients started bDMARD in their fifth decade of life, after a median disease duration of four years (Table I). The majority of patients were female with no differences between the types of bDMARD as regards age and gender attribution (Supplementary Table I). Rheumatoid factor or anti-CCP antibodies tested positive in 81% of the patients. Methotrexate (MTX) - median dose 20 mg per week and corticosteroids - median dose prednisolone (PDN) equivalent 10 mg/day had failed to control disease activity in 87% and 66% of patients, respectively. Treated dyslipidemia (51%) and arterial hypertension (41%) were frequently documented, 19% of patients suffered from chronic anxiety, 16% were smokers and 10% were obese. The median of the estimated 10-year survival using the Charlson comorbidity index was 90%.

**Result 2. Recall Patient Cohort: demographic and clinical features**

Recruitment was achieved in 77 patients, a major part of whom were between 47 and 66 years of age (Table II). As regards professional status almost half of the sample was retired (49%) and 10.5% unemployed. The majority (40.8%) only had 4 years of schooling; 11% had completed 12 years of schooling and 17% underwent a university education. Only 17% were single.

Over two thirds (79%) of the patients remained on bDMARD (n=61), the majority of whom were on etanercept and tocilizumab; 75% remained on the original bDMARD with an adequate compliance (Table III). Approximately one fifth of the patients stopped bDMARD (n=16), mostly due to infection but also because of primary or secondary failure or willfully due to subjectively controlled disease activity. One third of patients (n=22) switched from the original bDMARD, 8 having required further switches. Maximal number of 3 and 4 switches occurred in single patients. After bDMARD onset, MTX use reduced from 95 to 22% (p=0.002, Chi square test between frequencies). Likewise, steroid use significantly decreased from 74 to 30% (p<0.001, Chi square test between frequencies), halving the prednisolone equivalent dose to a median of 5 mg/day. Of note, the frequency of steroid use was slightly higher in those patients that discontinued bDMARD. Approximately 40% presented hand deformities, but the median number of deformities per patient was generally low. Dyslipidemia (53%) and arterial hypertension (43%) were equally distributed among the participants but chronic anxiety (18%), smoking (14%) and obesity (10%) were only registered in females. The original age difference between males and females was no longer present, with no other difference between sexes as regards demographic features, disease duration from diagnosis to recall, onset of first bDMARD and follow-up. Unlike before, the Charlson comorbidity index was now higher in men than women, estimating a lower 10-year survival for the former (p=0.019) (Supplementary Table II).

At recall, DAS28-ESR and HAQ were significantly lower when compared to the pre-bDMARD values, both with a p value <0.001 (Wilcoxon Signed Rank test). However the median DAS28-ESR of 3.2 (IQR 2.390 – 3.950) was borderline between low and moderate disease activity and the median HAQ-DI index was 1.310 (IQR 0.500 – 1.810), indicative of mild to moderate disability. Additionally, at recall, there was no significant difference in DAS28-ESR or HAQ when comparing patients on bDMARD with patients off bDMARDs (p=0.917 and 0.975, respectively - Mann Whitney-*U* test). Of note, the pre-bDMARD HAQ could only be obtained for 28 of the 77 patients at recall.

**Result 3. Recall Patient Cohort: HEALTH RELATED quality of life outcomes**

Lower scores on the SF-36 reflect poorer HR-QoL, particularly affecting the physical domains, general health perception and vitality in our patient cohort (Fig. 1). Due to missing values, the SF-36 Physical (PCS) and Mental Component Summaries (PCS) could only be calculated for 44 subjects with mean values of 37.7 ± 9.5 and 46.5 ± 11.6, respectively. Regarding EQ-5D-3L (Table III), the mean calculated score and VAS were 0.45 (± 0.3) and 60.64 (± 22.1), respectively. There were no significant differences in the EQ-5D-3L domains between men and women (Supplementary Table II). Moderate yet significant correlations were found between PCS, MCS and EQ-5D-3L mean score and VAS (Supplementary Table III).

 Full data as regards professional status are shown in Supplementary Table IV. Unemployed patients (n=7) had a significantly lower EQ-5D Portuguese tariff when compared to employed patients (n=19) (p=0.012, T-test), with a similar age; even though not significantly, unemployed patients had higher DA28, HAQ and number of deformities in comparison to the latter.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |

**Result 4. Demographic, clinical and therapeutic characterization of patients who died or were lost to follow-up**

Patients lost to follow-up were younger than the group as a whole, emigrated or returned to their country of origin or followed their physician to another hospital center (Table IV). The estimated 10-year survival rate at the time of first biologic therapy was significantly different between the deceased patients and the recall group (p=0,006) with median values of 65 (29 – 77) and 90 (77 - 90), respectively (Supplementary Table V).

**DISCUSSION**

Our Unit is dedicated to the treatment of patients with systemic autoimmune diseases including RA. We officially started treating RA patients with biological therapy in 2002, our first patient ongoing regular follow-up since treatment onset. With a median age of 50 years, our patients presented a high disease activity (median DAS28 of 5.30) and a high HAQ disability index (median 2.00) despite sDMARD therapy, at pre-bDMARD onset. These indices are known to be inter-related and long known to predict irreversible damage, physical and work disability and mortality.**22-23**

In our cohort, a high risk group of patients, with a potentially productive work-life, initiation of bDMARD occurred at a median of four years after RA onset. A recent meta-analysis of 36 randomized clinical trials comparing the standard doses of the five anti-TNF inhibitors combined with MTX to MTX mono-therapy described trial participants with a mean age varying from 48.4 to 60.7 years and a mean duration of disease from 0.2 to 11 years,**24** effectively meaning that the median therapeutic delay of four years, in our patient population, is probably not that prolonged when compared to others. Lack of access to specialist care may significantly contribute to the therapeutic delay. The Portuguese register Reuma.pt provides longitudinal information for over 7000 patients with RA at a national level.**25** Patients' access to biologics in RA stood at 7% in 2010 (12 percentage points below the average of European selected countries)**26** having tripled from 2007 to 2012.**27** Low education, on the other hand, may contribute to poor health literacy (40.8% of our patients only had 4 years of schooling) but of note, the latter has also been found to be relatively common among those with a high level of education.**28**

Due to the retrospective nature of our study we are unable to assess the degree of irreversible joint damage already present at the time bDMARD was started and which might have been prevented through earlier treatment. At recall, 22 of 54 patients presented hand deformities but the highest number of deformities per patient was 2.25. Remission or LDA as determined by DAS28 was found in 51% of patients. Disappointingly, 37% of patients presented with moderate and 11% with high disease activity. Even though significantly lower, HAQ disability index continued to reveal severe functional disabilities.

After a median duration of 7 years, most patients (79%) remained on bDMARD, retaining the original medication (etanercept). Discontinuation of bDMARD occurred primarily due to infection (38%) followed by treatment failure (26%). Our data contrasts with that of the Rheumatic Diseases Portuguese Register (Reuma.pt) of bDMARD treated patients after 13 years of prospective follow-up. In the latter, a higher frequency (50%) discontinued their first bDMARD mainly due to inefficacy (55%) with a much lower frequency of infections (4 %).**29** Of note, distinguishing those patients who died, the Charlson co-morbidity index was significantly higher at treatment onset and bDMARD was discontinued more frequently than in the recall group.

When compared to the frequencies of employed Portuguese persons (pordata.pt - 2017), the majority of whom have been through more than four years of schooling, our group of patients may have been at a disadvantage. On the other hand, the mean national age for retirement in Portugal in 2018 was 62.6 years, corresponding to the median age of our patients. Not surprisingly, at recall, almost 50% of our patients were pensioners. The median age of the unemployed patients (57.5 years) was nearing retirement time but it should be noted that despite bDMARD therapy, they had the highest disease activity, functional impairment and the lowest EQ-D5-3L score. This is in line with a recent Portuguese study that recalled a similarly high HAQ value for unemployed albeit younger RA patients.**30**

The mean EQ-5D-3L calculated with the Portuguese tariff was 0.45 (± 0.3), effectively placing our RA patients at a low score as regards HR-QoL. Interestingly, baseline mean EQ-5D-3L and HAQ values for a Greek population of RA patients were 0.57 and 0.75, (our values being 0.45 and 1.3) respectively. In this, higher HR-QoL scores clearly correlated with a lower functional impairment as measured by HAQ.31 We nevertheless believe that our therapeutic strategies have provided benefit as evidenced by a decrease in disease activity and improvement in the disability index.

We consider the following limitations. Due to the retrospective nature of the study we could not assess H-QoL indices from baseline and as such could not attempt to verify both the efficacy of particular drug regimens or compare them and how many patients became work-disabled due to disease. As bDMARD therapy was started late in the course of disease, we cannot assess if those who started early attained added clinical improvement compared with patients with a delayed start of therapy. Moreover, the dynamic nature of RA therapy cannot be reflected in this cross-sectional design. After recall some of the patients who had moderate or high disease activity were switched to alternative therapies that proved effective; other patients that were controlled subsequently lost response.

**CONCLUSIONS**

The use of bDMARD provided therapeutic benefit as reflected by a significant decrease in DAS28, HAQ and steroid use. There were few hand joint deformities per patient. The presence of comorbidities had an impact on mortality. The majority of patients retained the original bDMARD, few switches were required and the major cause for bDMARD interruption was infection. Nevertheless the mean EQ-5D-3L scores were low, indicating a poor HR-QoL, the smaller impact on the mental component domains of SF-36 possibly invoking less suffering. Earlier onset of therapy may have prevented deformities and residual irreversible functional incapacity. Increased literacy, access to healthcare and new therapeutic choices can be expected to contribute to earlier diagnosis and remission and improved overall outcomes in the years to come.

**ACKNOWLEDMENTS AND TASKS:**

Secretarial Assistance: Ana Martins

Medical care: Nuno Riso for prior coordination and longstanding commitment to the Unit.

MF, AF, ALO, ACF, PM, AVT, MV, CR, MJF and AP retrieved patient data, CM, MFMF and CR performed statistical analysis, MF, CM and MFMF wrote the manuscript, MFMF takes overall responsibility for the manuscript.

**REFERENCES**

1. Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. *Joint Bone Spine.* 2013;80(1):29-33.

2. Chester Wasko M, Dasgupta A, Ilse Sears G, Fries JF, and Ward MM. Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. *Arthritis Care Res (Hoboken).* 2016;68(5):706-10.

3. Gibofsky A. Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis. *Am J Manag Care.* 2014;20(7 Suppl):S136-44.

4. Curtis JR, and Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. *Clin Ther.* 2011;33(6):679-707.

5. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis.* 2014;73(3):492-509.

6. Rein P, and Mueller RB. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. *Rheumatol Ther.* 2017;4(2):247-61.

7. Kotyla PJ. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients? *Biomed Res Int.* 2018;2018:7492904.

8. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.

9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988;31(3):315-24.

10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis.* 2010;69(9):1580-8.

11. Charlson ME, Pompei P, Ales KL, and MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-83.

12. van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). *Clin Exp Rheumatol.* 2014;32(5 Suppl 85):S-65-74.

13. Fries JF, Spitz P, Kraines RG, and Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum.* 1980;23(2):137-45.

14. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum.* 1993;36(6):729-40.

15. Bruce B, and Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. *J Rheumatol.* 2003;30(1):167-78.

16. Maska L, Anderson J, and Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). *Arthritis Care Res (Hoboken).* 2011;63 Suppl 11:S4-13.

17. Borah BJ, Huang X, Zarotsky V, and Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. *Curr Med Res Opin.* 2009;25(6):1365-77.

18. Ferreira PL. [Development of the Portuguese version of MOS SF-36. Part I. Cultural and linguistic adaptation]. *Acta Med Port.* 2000;13(1-2):55-66.

19. Ferreira PL. [Development of the Portuguese version of MOS SF-36. Part II --Validation tests]. *Acta Med Port.* 2000;13(3):119-27.

20. Ferreira LN, Ferreira PL, Pereira LN, and Oppe M. The valuation of the EQ-5D in Portugal. *Qual Life Res.* 2014;23(2):413-23.

21. Ferreira LN, Ferreira PL, Pereira LN, and Oppe M. EQ-5D Portuguese population norms. *Qual Life Res.* 2014;23(2):425-30.

22. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, and Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis Rheum.* 1984;27(8):864-72.

23. Wolfe F, Michaud K, Gefeller O, and Choi HK. Predicting mortality in patients with rheumatoid arthritis. *Arthritis Rheum.* 2003;48(6):1530-42.

24. Graudal N, Kaas-Hansen BS, Guski L, Hubeck-Graudal T, Welton NJ, and Jurgens G. Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis-A Network Meta-Analysis of 36 Randomized Controlled Trials. *Int J Mol Sci.* 2019;20(18).

25. . http://reuma.pt/pt\_PT/docs/ONDOR\_reumapt.pdf. 2018.

26. Laires PA, Exposto F, Mesquita R, Martins AP, Cunha-Miranda L, and Fonseca JE. Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. *Eur J Health Econ.* 2013;14(6):875-85.

27. Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Bijlsma JW, and Leufkens HG. Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries. *Health Policy.* 2012;104(1):76-83.

28. van der Heide I, Wang J, Droomers M, Spreeuwenberg P, Rademakers J, and Uiters E. The relationship between health, education, and health literacy: results from the Dutch Adult Literacy and Life Skills Survey. *J Health Commun.* 2013;18 Suppl 1:172-84.

29. Gomes JL, Sepriano A, Eusebio M, Serra S, Fonseca JE, Saavedra MJ, et al. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt. *Acta Reumatol Port.* 2019;44(1):57-64.

30. Guerra MG, Vieria R, Ganhao S, Rodrigues J, Fonseca D, Videira T, et al. First steps to understand productivity loss in Portuguese patients with rheumatoid arthritis. *Acta Reumatol Port.* 2019.

31. Boumpas DT, Sidiropoulos P, Settas L, Szczypa P, Tsekouras V, Hernandez Daly AC. Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study. Health Qual Life Outcomes 2019;17:73.

TABLES

**Table I. Baseline demographic and clinical characteristics**

|  |  |  |
| --- | --- | --- |
|  | Original cohort | Recall cohort |
| Number of Patients | 94 | 77 |
| Male:Female | 19:75 | 14:63 |
| Caucasian, n (%) | 86 (91) | 71 (92) |
| Age (y), median (IQR) | 50 (42 - 57)\* | 63 (55 – 71) |
| Age (y) bDMARD started, median (IQR) | 56 (47 – 62) | 56 (49 – 61) |
| Disease duration (y) from time of diagnosis to first bDMARD, median (IQR) | 4 (1 - 9) | 4 (1 – 9) |
| Either or anti-CCP/RF positive, n (%) | 76 (81) | 61 (79) |
| Anti-CCP/RF negative, n (%) | 18 (19) | 16 (21) |
| **Prior to bDMARD:** |
| Prednisolone, n (%) | 62 (66) | 57 (74) |
| Prednisolone equivalent mg/day, median (IQR) | 10 (5 – 12) | 10 (5 – 10)\*\* |
| Methotrexate, n (%) | 82 (87) | 73 (95) |
| Methotrexate mg/day, median (IQR) | 20 (15 – 20) | 20 (13 – 20) |
| Pre-bDMARD DAS 28 – ESR, median (IQR)  | 5,31 (4.51 – 6,29) | 5.060 (4.500 -5.998) |
| Number of Patients for which DAS available | 75 | 62 |
| - high disease activity (HDA) > 5.1, n (%) | 52 (46) | 31 (50) |
| - moderate disease activity (MDA) ≥ 3.2 and ≤5.1, n (%) | 30 (40) | 28 (45) |
| - low disease activity (LDA) ≥ 2.6 and < 3.2, n (%) | 0 | 0 |
| - remission < 2.6, n (%) | 3 (4) | 3 (5) |
| Pre-bDMARD HAQ, median (IQR) initial n=33; recall n=27 | 2.00 (1.47 – 2.53) | 2.00 (1.44 – 2.49) |
| On bDMARD, n (%) | 94 (100) | 61 (79) |
| **bDMARD:** |  |  |
| Infliximab, n (%) | 3 (3) | 1 (1,5) |
| Etanercept, n (%) | 55 (59) | 31 (51) |
| Adalimumab, n (%) | 14 (15) | 5 (8) |
| Golimumab, n (%) | 2 (2) | 2 (3) |
| Rituximab, n (%) | 6 (6) | 6 (10) |
| Tocilizumab, n (%) | 14 (15) | 15 (25) |
| Abatacept, n (%) | 0 | 1 (1.5) |
| **Comorbidities:**  |  |  |
| Benign Tumors n (%) | 2 (1) | 0 |
| Malignancy | 6 (6) | 2 (2) |
| Active smoking, n (%) | 12 (16) | 11 (14) |
| Dyslipidemia, n (%) | 48 (51) | 41 (53) |
| Arterial hypertension, n (%) | 39 (41) | 33 (43) |
| Obesity, n (%) | 9 (10) | 8 (10) |
| Chronic anxiety/depression disorder, n (%) | 18 (19) | 14 (18) |
| Charlson Comorbidity Index at time bDMARD started, median (IQR) | 2 (2 -3) | 2 (2 -3) |
| Estimated 10-year survival at the time bDMARD started, median (IQR) | 90 (77 – 90) | 90 (77 – 90) |

\*age at diagnosis

\*\*dose not known in 6 females and 2 males

**Table II. Age distribution, professional situation, schooling, marital status and socio-economic status at recall\***

|  |  |
| --- | --- |
| **Age range (y) (n=77)** | N (%) |
| 27 - 36 y | 1 (13) |
| 37 – 46 y | 5 (6.5) |
| 47 – 56 y | 17 (22.1) |
| 57 – 66 y | 26 (33.8) |
| ≥ 67 y | 28 (36.3) |
| **Professional Situation\*** |  |
| Employed | 21 (27.6) |
| Unemployed | 8 (10.5) |
| Retired | 37 (48.7) |
| Student | 2 (2.6) |
| Homemaker | 6 (7.9) |
| Other | 2 (2.6) |
| **Schooling\*** |  |
| Cannot read or write | 1 (1.3) |
| Can read and write but no schooling | 3 (3.9) |
| First 4 years | 31 (40.8) |
| First 6 years | 4 (5.3) |
| First 9 years | 15 (19.7) |
| Completed schooling (12 years) | 9 (11.8) |
| University degree | 13 (17) |
| **Marital status\*** |  |
| Single | 13 (17.1) |
| Married | 43 (56.6) |
| Divorced | 11 (14.5) |
| Widow | 9 (11.8) |

\*missing information in one patient

**Table III. Disease duration, therapy, disease activity, functional status and EQ-5D-3L at recall**

|  |  |
| --- | --- |
| Number of patients | 77 |
| Disease duration (y) from diagnosis to recall, median (IQR) | 12 (7 – 18) |
| Duration of follow-up from onset of bDMARD to recall, median (IQR) | 7 (4 – 9) |
| Continued bDMARD by recall, n (% of 77) | 61 (79) |
| Last bDMARD: |  |
|  Etanercept, n (%) | 31 (51) |
|  Adalimumab, n (%) | 5 (8) |
|  Tocilizumab, n (%) | 15 (25) |
|  Infliximab, n (%) | 1 (1,5) |
|  Rituximab, n (%) | 6 (10) |
|  Golimumab, n (%) | 2 (3) |
|  Abatacept, n (%) | 1 (1.5) |
| Retained original bDMARD, n (%) | 46 (75) |
| Compliance with bDMARD over the past year (n=56) | 45 (80) |
| Had discontinued bDMARD by recall, n (% of 77) | 16 (21) |
| Reason for discontinuation: |  |
| 1.     Primary failure to bDMARD, n (%16) | 2 (13) |
| 2.     Secondary failure to bDMARD, n (%16) | 2 (13) |
| 3.     Infection, n (% 16) | 6 (38) |
| 4.     Neoplastic disease, n (% 16) | 1 (6) |
| 5.     Remission, n (% 16) | 3 (19) |
| 6.     Other, n (% 16) | 2 (13) |
| Retained original bDMARD, n (% of 61) | 46 (75) |
| Switched bDMARD, n (% of 61)\*  | 22 (36) |
| 1.    Once, n (% 22) | 14 (64) |
| 2.    Twice, n (% 22) | 6 (27) |
| 3.    Thrice, n (% 22) | 1 (5) |
| 4.    Fourth, n (% 22) | 1 (5) |
| \*5 patients switched and then stopped |  |
| Compliance with bDMARD over the past year (n=56) | 45 (80) |
| Methotrexate, n (% of 77) | 17 (22) |
| Methotrexate dose mg/week, median (IQR) | 15 (10 – 20) |
| Steroids, n (% of 77) | 23 (30) |
| Prednisolone equivalent mg/day, median (IQR) | 5 (5 – 10) |
| Steroids plus bDMARD, n (% of 61) | 16 (26) |
| Steroids having discontinued bDMARD, n (% of 16) | 7 (43) |
| Deformities, n (%) – 54 patients evaluated | 22 (41) |
| Deformities/patient, median (IQR)\*\*  | 0.5 (0 – 2.25) |
| Recall HAQ, median (IQR) n=77 | 1.310 (0.500 – 1.810) |
| Recall DAS 28 – ESR, median (IQR) n=72 | 3.200 (2.390 – 3.950) |
| - high disease activity (HDA) > 5.1, n (%) | 8 (11) |
| - moderate disease activity (MDA) ≥ 3.2 and ≤5.1, n (%) | 27 (37) |
| - low disease activity (LDA) ≥ 2.6 and < 3.2, n (%) | 18 (25) |
| - remission < 2.6, n (%) | 19 (26) |
| **EQ-5D 3L (n=76)** |  |
| Mobility, mean (SD) | 1,72 (0.51) |
| Personal Care, mean (SD) | 1,65 (0.58) |
| Usual Activities, mean (SD) | 1,76 (0.59) |
| Pain and Unwell, mean (SD) | 1,97 (0.57) |
| Anxiety and Depression, mean (SD)  | 1,72 (0.72) |
| EQ-5D 3L Visual Analogue Scale (VAS), mean (SD) | 60,64 (22.07) |
| EQ-5D 3L score –Portuguese tariff, mean (SD) | 0,45 (0.3) |

**Table IV. Demographic and clinical characterization of patients who died or lost to follow-up**

|  |  |
| --- | --- |
| **Characteristics** |  |
| **Alive but lost to follow-up, n (% of 94)** | 7 (7) |
| - Female: Male | 5:2 |
| - Went to live abroad, n | 4 |
| - Followed at another hospital in Portugal, n | 3 |
| - Age (y) bDMARD started, median (IQR) | 44 (36 – 54.5) |
| - Patient age (y) at the time lost to follow-up, median (IQR) | 47 (39 – 60) |
| - Disease duration (y) from time of diagnosis to first bDMARD (median ± IQR) | 2 (1 – 4) |
| - Disease duration (y) at the time lost to follow-up, median (IQR) | 4 (3 – 5) |
| - Either or anti-CCP/RF positive | 5 |
| - Anti-CCP and RF negative | 2 |
| - Charlson comorbidity index at the time bDMARD started, median (IQR) | 1 (1 – 2) |
| - % Estimated 10 year survival at the time bDMARD started, median (IQR) | 96 (86.5 – 96) |
| - bDMARD: |  |
|  - Etanercept, n; later switch to rituximab, n | 4 ; 1 |
|  - Tocilizumab, n | 1 |
|  - Infliximab switched to abatacept, n | 1 |
| **Death, n (% of 94)** | 6 (6) |
| - Female: Male | 3:3 |
| - Cause of death unknown | 3 |
| - Cause of death known:  |  |
|  - Pneumocystis pneumonia | 1 |
|  - Pulmonary tuberculosis | 1 |
|  - Stroke | 1 |
| - Age (y) bDMARD started, median (IQR) | 60 (57 – 63) |
| - Age (y) at time of death, median (IQR) | 66 (61 – 67) |
| - Disease duration (y) from time of diagnosis to first bDMARD (median ± IQR) | 7 (3 – 11) |
| - Disease duration (y) at time of death (median ± IQR) | 16 (8 – 21) |
| - Either or anti-CCP/RF positive, n (%) | 7 (100) |
| - Charlson comorbidity index at time bDMARD started, median (IQR) | 3.5 (3 – 4.75) |
| - % Estimated 10 year survival at time bDMARD started, median (IQR) | 65 (29 – 77) |
| On methotrexate and bDMARD at time of death (n=2): |  |
|  - Etanercept, n | 1 |
|  - Adalimumab, n | 1 |
| Off bDMARD at time of death (n=4): |  |
| - Previous etanercept, n | 2 |
| - Previous adalimumab | 1 |
| - Previous rituximab | 1 |

Figure 1. Health-related quality of life using the SF-36 health survey. Values are shown for each dimension: physical functioning (PF), role limited by physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limited by emotional problems (RE), and mental health (MH).